Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study
NCT00341198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700
Last updated 2017-07-02
Summary
Autoimmune diseases may involve nearly any organ and are characterized by abnormal activation or response of certain cells. Evidence suggests that farm work, exposure to silica from farming activities and exposure to pesticides may contribute to the development of autoimmune disease. Associations between autoimmune diseases and farming, however, have not been extensively investigated, and exposure data in the currently available studies are extremely limited.
One of the major challenges in conducting population-based research on autoimmune diseases is case ascertainment. Self-report of previous diagnosis has proven to be unreliable. This protocol outlines a strategy to confirm self-reported diagnoses of systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and Sjogren syndrome) within the Agricultural Health Study group (AHS; a group of licensed pesticide applicators and spouses who completed a questionnaire). The confirmed cases will constitute a refined case group to allow analyses of pesticides and other farming-related exposures as possible risk factors for these diseases using data that have already been collected.
Subjects will be selected from participants in the AHS who reported one of the diseases being studied. A short telephone interview will be conducted with participants, who will be requested to provide written consent for review of information from medical records. To confirm the self-diagnosis, participants' physicians will be contacted. Specific information will be requested in the form of a checklist. Responses will be reviewed for evidence of diagnosis and classified as confirmed, probable, physician-diagnosed, or unconfirmed.
Secondary objectives of this study are to:
* assess the correct interpretation of conflicting self-reports that are provided at two different times.
* evaluate the usefulness of specific questions that could potentially be used in future studies to validate self-reported cases of rheumatoid arthritis in men.
Conditions
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-04-02
- Completion
- 2006-12-12
Countries
- United States
Study Locations
More Related Trials
-
Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
NCT03254823 ·Status: COMPLETED
-
Autoantibodies Prevalence During Checkpoint Inhibitor Treatment
NCT04220034 ·Status: COMPLETED
-
Disease Progression and Activity in Patients With Systemic Lupus Erythematosus
NCT00339261 ·Status: COMPLETED
-
Immunome Project Consortium for Autoinflammatory Disorders
NCT03919110 ·Status: COMPLETED
-
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
NCT01408576 ·Status: COMPLETED ·Phase: PHASE3
-
T and B Cell Responses in Autoimmune Diseases
NCT01947036 ·Status: TERMINATED
-
Clinical Autoinflammatory Disease Cohort
NCT07126145 ·Status: NOT_YET_RECRUITING
-
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT04810754 ·Status: UNKNOWN ·Phase: PHASE2
-
Neutrophil Extracellular Traps in Systemic Sclerosis
NCT03374618 ·Status: COMPLETED ·Phase: NA
-
Monitoring the IMmUological TOXicity of Drugs
NCT03480529 ·Status: COMPLETED
-
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
NCT05426902 ·Status: COMPLETED ·Phase: NA
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2
-
Vitamin D3 in Systemic Lupus Erythematosus
NCT00710021 ·Status: COMPLETED ·Phase: PHASE2
-
C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease
NCT06935474 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
NCT03003572 ·Status: RECRUITING
-
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
NCT05866861 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases
NCT04690816 ·Status: COMPLETED
-
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05000216 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
NCT05430854 ·Status: TERMINATED ·Phase: PHASE2
-
PRediction Of Flares In Lupus With autoantibodiEs and Chemokines
NCT04951427 ·Status: UNKNOWN
-
Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases
NCT01934764 ·Status: UNKNOWN